42 results on '"McKone E"'
Search Results
2. 485 Measuring adherence to chronic therapies over 2 years of treatment with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis—the RECOVER Study
3. 196 Airway infection and inflammation in people with cystic fibrosis treated with 1 year of elexacaftor-tezacaftor-ivacaftor—the RECOVER study
4. 144 Changes in airway nitric oxide in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study
5. 142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11
6. 138 Clinical outcomes in people with cystic fibrosis after 2 years of elexacaftor-tezacaftor-ivacaftor: Results from the RECOVER study
7. 83 Evaluation of ivacaftor and antibiotic therapies on breath biomarkers for Pseudomonas aeruginosa and Staphylococcus aureus in cystic fibrosis
8. P127 Twenty years and counting: longitudinal trends in real-world primary outcomes for people with cystic fibrosis in Ireland and the evolution of a registry
9. P044 Oral and intravenous antibiotic requirements prior to and following elexacaftor/tezacaftor/ivacaftor treatment in children and adults with cystic fibrosis – analysis from the RECOVER Study
10. P038 Direct measurement of short-term adherence to elexacaftor/tezacaftor/ivacaftor and changes in sweat chloride levels – results from the RECOVER Study
11. P005 An audit on adherence to guidelines on screening colonoscopies in an adult cystic fibrosis centre
12. EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study
13. EPS6.06 Impact of 6 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with cystic fibrosis – The RECOVER study
14. EPS6.05 A phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)
15. EPS6.02 Elexacaftor/tezacaftor/ivacaftor results in substantial improvements in chest CT scores in people with cystic fibrosis aged 12 and above over one year of treatment
16. WS05.03 A phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance in people with cystic fibrosis (CF) and abnormal glucose metabolism
17. WS06.02 Impact of one year of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in people with cystic fibrosis in a real-world setting – the RECOVER study
18. 565: Significant reduction in abdominal symptoms assessed with CFAbd score over 4 weeks of treatment with elexacaftor/tezacaftor/ivacaftor—First results from the RECOVER study
19. 564: Impact of elexacaftor/tezacaftor/ivacaftor treatment on clinical outcomes in people with CF in a real-world setting—The RECOVER trial
20. P156 Mycobacterium abscessus treatment in adult patients with cystic fibrosis: case series and review
21. P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study
22. P071 Real-world pregnancy data and outcomes in an era post-CFTR modulation therapies: an Irish centre's perspective
23. P042 RECOVER - the Real World Clinical Outcomes with Novel Modulator therapy combinations in people with cystic fibrosis
24. P267 An evaluation of the nutritional status of Irish adults attending the National Referral Centre for Adult Cystic Fibrosis in 2019
25. P102 Mycobacterium abscessus treatment complexity in adult patients with cystic fibrosis: case series and review
26. ePS3.02 Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis
27. P208 Impact of ivacaftor treatment disruption on clinical outcomes: a single centre study
28. P176 Detection of respiratory viruses in cystic fibrosis: comparison of nasal FLOQ Swabs™ and sputum using the FilmArray® platform
29. P113 Treatment of adult cystic fibrosis patients with ceftolozanetazobactam with a previous adverse drug reaction to piperacillintazobactam
30. P066 Disease progression and burden in patients with cystic fibrosis homozygous for F508del across Europe in an observational registry (VOICE Study)
31. P023 Impact of lumacaftor/ivacaftor (Orkambi®) on proton pump inhibitor use in adult cystic fibrosis patients
32. ePS03.4 Improved rate of decline in percent predicted FEV1 (ppFEV1) is not associated with acute improvement in ppFEV1 in patients with cystic fibrosis (CF) treated with ivacaftor
33. WS18.5 Direct medical cost of CF care in the Irish public healthcare system
34. WS02.4 Short-term and long-term effects of ivacaftor treatment on sputum microbiota in people with the G551D CFTR mutation
35. WS7.4 Inhaled aztreonam lysine (Cayston) therapy significantly improves lung function, weight, hospitalisations and excerbation rates prospectively – an Irish and UK real world experience
36. WS3.1 The effect of ivacaftor on the rate of lung function decline in CF patients with a G551D-CFTR mutation
37. WS5.4 Can registry data be used to examine cystic fibrosis (CF) health service utilisation? Perspectives of the Irish CF Registry
38. 295 Pregnancy outcomes in female cystic fibrosis patients attending an adult CF center
39. 250 Vitamin D deficiency and thoracic kyphosis in adult cystic fibrosis patients
40. 213 Study evaluating the effect of weekends on activity and inflammatory markers in adult patients with cystic fibrosis
41. WS19.2 Development and application of quality improvement questionnaire in adults with cystic fibrosis
42. WS6.4 Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR Mutation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.